

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/047,072	01/15/2002	Ralph M. Steinman	MER-011DIV/112917.138US2	7452
23483 7	590 08/05/2002			
HALE AND DORR, LLP			EXAMINER	
60 STATE STI BOSTON, MA			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	0
			DATE MAILED: 08/05/2002	L

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

Applicant(s)

10/047,072

Sreinman et al.

Examiner

G.R. Ewoldt

Art Unit **1644** 



The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.				
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In	no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within t	ne statutory minimum of thirty (30) days will be considered timely.			
<ul> <li>If NO period for reply is specified above, the maximum statutory period will apply a Failure to reply within the set or extended period for reply will, by statute, cause to</li> </ul>	ne application to become ABANDONED (35 U.S.C. § 133).			
<ul> <li>Any reply received by the Office later than three months after the mailing date of earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>	this communication, even if timely filed, may reduce any			
Status				
1) Responsive to communication(s) filed on	·			
	tion is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposition of Claims				
4) 💢 Claim(s) <u>1-8</u>	is/are pending in the application.			
4a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) Claim(s)	is/are allowed.			
6) Claim(s)	is/are rejected.			
7)	is/are objected to.			
8) 💢 Claims <u>1-8</u>	are subject to restriction and/or election requirement.			
Application Papers				
9) $\square$ The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/arc	e a) $\square$ accepted or b) $\square$ objected to by the Examiner.			
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on	is: a) □ approved b) □ disapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.				
12) The oath or declaration is objected to by the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120				
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) $\square$ All b) $\square$ Some* c) $\square$ None of:				
1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No				
application from the International Bur				
*See the attached detailed Office action for a list of t				
14) Acknowledgement is made of a claim for domesti				
a) The translation of the foreign language provision				
15) Acknowledgement is made of a claim for domesti	c priority under 35 U.S.C. 33 120 and/or 121.			
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).			
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawling Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)				
<del></del>				

Serial No. 10/047,072 Art Unit 1644

## DETAILED ACTION

- 1. This application contains inventions drawn to patentably distinct species. Applicant is required under 35 U.S.C. § 121 to elect:
- A) a **specific** cytokine or combination of cytokines, such as one of those listed in Claim 6,
- B) and list all Claims readable thereon including those subsequently added. Currently Claims 1-8 are generic.
- 2. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

The different cytokines comprise significantly different biological properties as they relate to the growth of dendritic cells, e.g., TNF- $\alpha$  is thought to be required for the growth of human dendritic cells whereas other cytokines such as IL-12 are not. Therefore, the species are independent and patentable over one another.

- 3. Applicant is advised that the response to this requirement to be complete must include an election of the species to be examined even though the requirement be traversed.
- 4. Any inquiry concerning this communication from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

G.R. Ewoldt, Ph.D.

Patent Examiner

Technology Center 1600

August 5, 2002